Welcome back DOV! I think management needs to be pushed to give some colour and elaborate on the trial results on the 40 investigator lead studies. Furthermore where are the European clinics offering our cellution for approved indications?
I applaud April. She probably knows the value in social media. Fact is most of the indications that regen med is targeting right now are diseases that effect older people. blindness, heart disease, ect.
These older patients don't get their story out like the younger generation.
Quick approval for these new therapies will have to come from the ground up IMO
The travesty is that the FDA states they are concerned with safety and these people are dying.
No updates on the website since April 2012. My guess is they were regulatory stopped out. Hopefully they will be open soon due to passing of the new regenerative med laws.
Big difference from before is we now have money and cancer vaccines are being validated... big difference. Garo has been accumulating for 2 years taking a position using his own capital Now he has a good chunk of options also. I believe Garo is the largest shareholder. Now he's going to execute his plan and become very wealthy. He does have altruistic motives that drive him and validate his pursuit of wealth though. His Armenian charity comes to mind along with battling cancer. Garo is a pioneer and a good man IMO
A new movement is afoot in the USA to introduce some common sense. It's starting first in Arizona.
BY: Mary Lou Byrd
February 21, 2014 11:20 am
A bill allowing the terminally ill to use experimental drugs not yet approved for use by the Federal Drug Administration has advanced to the full House in Arizona.
Arizona lawmakers passed the bill out of committee and in the next three weeks both chambers of the legislature could vote on it. It would then need to be approved by voters in November.
The Right to Try law would give those who have exhausted all other treatment options the use of non-FDA approved drugs. According to the Goldwater Institute, similar laws are under consideration and in different stages of the legislative process in seven other states.
Supporters of the bill are optimistic it will become law in Arizona and that other states will follow suit.
“This is a fundamental right for people to have,” said Christina Corieri, a health care policy analyst at the Goldwater Institute, which helped craft the law. “They have a fundamental right to save their own life, and there shouldn’t be a bureaucrat in the picture.”
Corieri said patients themselves should have the right to decide if they want to take these drugs, which may or may not have potential side effects.
“We know the side effect that will occur if they don’t access these drugs—they are going to die,” said Corieri.
Frank Burroughs, cofounder of the Abigail Alliance, which advocates for wider access to developmental drugs, said Arizona’s actions are a hopeful sign.
“I am very hopeful right now,” said Burroughs. “At times, this business could feel very hopeless.”
Burroughs’ daughter, Abigail, died at the age of 21 after exhausting all FDA approved drugs. Her access to the drug Erbitux was denied, even though it was showing promising signs in early clinical trials.
The FDA approved Erbitux three-and-a-half years after Abigail’s death.
Burroughs said he believes Abigail would be alive tod
Using t cells but they still have to identify the antigens.That's Agenus specialty.Personalixed cancer treatment will be the new paradigm.
Google lukemia cure
He says he has a chance to exit some of his investments in the next 12 months....Maybe japanese deal to give up Asia for some big bucks and keep a percent of sales too.Remember they are giving a huge market cap to Japanese regen med companies
Former Wisconsin Gov. Thompson Wants to Form Angel Fund
Jeff Engel2/13/14Follow @XconomyWI
Share and Comment
Leave a Comment
Order a Reprint
E-mail this Story
Former Wisconsin governor Tommy Thompson has aspirations for starting an early-stage investment fund—that’s if he can achieve a few exits this year with his current personal investments.
Thompson made the comments Thursday afternoon at a luncheon in Wauwatosa, WI, hosted by the Wisconsin Innovation Network, an arm of the Madison-based Wisconsin Technology Council.
Thompson held the state’s top office from 1987-2001, and then served as secretary of the U.S. Department of Health and Human Services under former President George W. Bush. He went on to work as a senior advisor to Deloitte and founded the Deloitte Center for Health Solutions.
More recently, the Republican lost a U.S. Senate race in 2012 against Wisconsin Democrat Tammy Baldwin.
Last year, he incorporated Thompson Holdings, an umbrella business overseeing a portfolio of more than 30 companies he has invested in and advises, primarily in the healthcare sector, he said.
Thompson said four of the companies in his portfolio are close to a potential exit this year.
“If I do [see exits in my investments], hopefully I’ll be able to set up an angel/venture fund,” Thompson told an audience of about 40 at the event held at the Crowne Plaza Hotel. “I’m not there yet, but we have the potential over the next 12 to 18 months… What we really, sincerely need is more angel investors [in Wisconsin].”
Thompson Holdings has only one Wisconsin company in its portfolio, Physicians Realty Trust, a Milwaukee-based healthcare real estate company that raised $120 million in an initial public offering last summer.
Other companies Thompson is involved with include Cytori Therapeutics, a San Diego-based company developing ways to treat cardiovascular disease and repair soft tissue defects through regenerative cell technologies. Thompson has served on Cytori’s board since 2011.
A Thompson spokesman declined to disclose how much Thompson Holdings has invested in its portfolio companies.
Wow great article WST You put in words what I have been trying to explain to some friends and family.
mass manufactured stem cells
Many years ago I noticed that one of the more prominent companies who was planning to mass manufacture adult stem cells for distribution like a drug made some interesting claims. They reported that they could get 10,000 doses of adult bone marrow stem cells out of a single donor. As someone who has as much clinical experience in the use of cultured stem cells as anyone in the world, I was intrigued. The number seemed way off. This week I learned the reason; most of these companies in FDA clinical trials using these mass manufactured stem cells are likely mass manufacturing cellular junk. Let me explain.
Adult stem cells will grow in culture to bigger numbers. In fact, this forms the basis of our Regenexx-C technology. Bone marrow is plated in a special culture system and exposed (in our case) to the patient’s own concentrated growth factors and this causes the stem cells to multiply to 100-1,000 times more than the starting number. Publicly traded, commercial cell therapy companies are doing the same thing, however, many have decided that it’s more profitable and better fits a Pharma model to take cells from young donors and grow those and then ship those in vials to doctors and hospitals. This is where the number 10,000 starts to become a problem that Wall Street investors seem to have missed. You see, adult stem cells are being used for their great safety profile. One of those added layers of safety is that unlike embryonic stem cells, they won’t grow indefinitely. In fact, they will only grow so long and then generally stop growing. To understand this next part, you’ll need to learn some cell culture terminology.
Each time cells growing in culture are fed, it’s called a “passage”. Once you start the culture process, it takes about 3-7 days for the cells to form colonies. Those cells are then placed into ever bigger flasks and fed (passaged) about every 2-3 days. So cells that have grown only a short time will be known by monikers like P1, P2, or P3 (first, second, or third passage). This is a critical number for the doctor and patient to know. Why? Because regrettably, the longer you grow adult stem cells, the less potent they become. So growing more is a balance between actually getting bigger numbers, but not growing them too long so that the cells aren’t any good. In fact, there are about 100 or more scientific papers in the medical literature that describe how cells grown too long are less effective-losing all sorts of abilities to heal or replace damaged tissue. This is where the commercial cell therapy industry has a huge problem.
Let’s return to our number 10,000. In fact, lets also add the number 100,000. These are the number of doses that most commercial mass manufactured stem cells therapy companies claim that they can grow from a single young donor. I knew this was an issue a few years back, because even on the best day, since these doses require 10-100 million cells each, we could only grow about 50 doses from a very young donor. Maybe, a real outstanding donor might grow 100 doses. However, how are these companies growing 10,000-100,000 doses? You guessed it, they’re growing the snot out of these cells. I learned this week, that most of these mass manufactured stem cells companies are routinely growing these cells to P6-P10! Yikes! This is the cell therapy equivalent of making someone slave in the mines for 22 hours a day! Almost all of the published research would point in the direction that by the time these cells exit the commercial culture process they are much less potent than they would have been if they had been grown to a more appropriate P2 or P3 stage. They are the cell therapy equivalent of using a copy machine to make a copy of a copy of a copy of a copy of a copy. The end result isn’t much like the original.
I’m sure many of these companies will argue that since they use young donors in the prime of their lives, this allows them to grow the heck out of these cells. While there may be a tiny kernel of truth in that argument, it really doesn’t hold water. In fact, a study from a large European University just showed much less clinical efficacy in treating transplant patients with young donor cells that were P3-P4 (grown much less than the commercial cells) versus P1-P2 cells. How big a difference? 75% of the patients who had the P1-P2 cells survived Graft vs. Host Disease (the severe rejection of an organ transplant) whereas only 21% of the patients who got P3-P4 cells lived! In context, these commercial cells are grown twice as long as the bad cells in this study. In addition, the medical literature is rife with studies that show that someone else’s cells are chewed up by the host’s immune system as they begin to differentiate into other cells-a hallmark of adult stem cells. So while you have the advantage of these off the shelf cells coming from a young donor, you have the disadvantage that they will get chewed up by the host patient’s immune system.
What’s interesting about this is that the commercial cell drug industry may have shot themselves in the foot. Because most of these cultured cells don’t have the ability to be protected by strong patents, the industry argued for strict over-regulation to box out competitors. They created a world where common tissues would be hyper-regulated as drugs, instead of being regulated less strictly as simple transplants. This dramatically increased the cost of mass manufacturing cells, as the regulatory cost of producing a cellular drug is much more than processing tissue. For example, stem cells grown using these drug production methods cost several thousand dollars a dose versus pennies a dose for chemical drugs. In addition, drugs need FDA clinical trials, but transplant tissues do not. Hence another several hundred millions dollars of cost was added to getting a “stem cell drug” to the bedside. As a result, the industry has apparently decided to cut corners by growing cells way too long and increasing the number of doses out of each donor. As discussed, while this reduces cost, it also likely seriously reduces efficacy.
The upshot? We’ve seen a rash of clinical trials out of these companies lately where the results have been either good, but not great or barely besting the statistical monkey on their back. Could one reason be less potent stem cells that have been grown way too long for their own good? Could a quest for better looking spreadsheets have overridden good medicine? Time will tell, but this is a very disturbing trend that should concern investors in these companies.
Yes but ACTC has 240 mil market cap which is way above ours. Hoping they will be uplisting with a reverse split within a month
Robert Lanza from ACTC wiil be on the show.Stocks up 50%in the last week.Great results coming out this week IMO
Lim is not concerned with the current share price. My thought is Cytori gets bought out by a Japanese company. The major shareholders are now Astellas Olympus and Lim
The Alliance for regenerative Medicine conference and lobby group will be the catalyst to propel the sector. I believe there has been a coordinated effort by the members to hold back discretionary news until the conference on Jan 13
Around or before that time I expect news will be released from ACTC regarding their embryonic phase 1 trial in treating blindness... I believe it will be spectacular.
Cytori has so much to divulge I think they could do a press release every 3 days for a month. Then there's ATHX, CUR, MESO and many others.
What we need is the media machine engaged, and I believe ACTC may start the ball rolling.
Remember it was the Democrats and Obama in his first term that changed the law to allow scientific funding for embryonic stem cells. Maybe the Democrats feel its time to take some credit for this decision.